跳至主要内容
临床试验/EUCTR2006-002278-24-IT
EUCTR2006-002278-24-IT进行中(未招募)不适用

A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency. - BPLG-005-RO

BIOPARTNERS GMBH0 个研究点目标入组 150 人开始时间: 2008年12月16日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1)Patients (male and female) who have completed the Visit 8 of preceding main study (BPLG-005) and are willing to continue their participation in an extension study.
  • 2)If female, women of child-bearing potential who are using a reliable method of contraception and be willing to use it throughout the study. A negative urine pregnancy test at Visit 0 is required for females of child-bearing potential.
  • 3)Written informed consent of the patient.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1)Evidence of active malignancy or growth of a previously stable tumor.
  • 2)Benign intracranial hypertension.
  • 3)Clinically significant respiratory, cardiac, hepatic, renal, neuromuscular disease.
  • 4)Non-compliance with medications, un-cooperativeness or drug abuse during the BPLG-005 study.
  • 5)Patients who are not able to comply with the study protocol for any reason.

研究者

相似试验

进行中(未招募)
不适用
A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.Growth hormone deficiency in adultsMedDRA version: 8.1Level: LLTClassification code 10056438Term: Growth hormone deficiency
EUCTR2006-002278-24-SEBioPartners GmbH150
进行中(未招募)
不适用
A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.Growth hormone deficiency in adultsMedDRA version: 8.1Level: LLTClassification code 10056438Term: Growth hormone deficiency
EUCTR2006-002278-24-CZBioPartners GmbH150
进行中(未招募)
不适用
A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.
EUCTR2006-002278-24-ATG Life Sciences Ltd.150
进行中(未招募)
1 期
A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.Growth hormone deficiency in adultsMedDRA version: 8.1 Level: LLT Classification code 10056438 Term: Growth hormone deficiency
EUCTR2006-002278-24-GBBioPartners GmbH150
进行中(未招募)
不适用
A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.Growth hormone deficiency in adultsMedDRA version: 8.1Level: LLTClassification code 10056438Term: Growth hormone deficiency
EUCTR2006-002278-24-FRBioPartners GmbH150